TP53 and breast carcinoma: Together our findings suggest that both SERMs and SERDs can function as radiosensitization agents in p53 wild-type and p53-mutant models of ER + breast cancer and add to a body of literature suggesting this may be an effective clinical strategy, especially in women at high risk for locoregional disease recurrence.